Drugs / BCD-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05739006 | Feb 2021 → Jun 2022 | melanoma, non-small cell lung carcinoma | Biocad | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05986331 | Jul 2022 → Dec 2023 | cutaneous melanoma | Biocad | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05739006 ↗ |
| Route | Intravenous | “BCD-201 200 mg by intravenous infusions once every 3 weeks” NCT05739006 ↗ |